Healthcare & Life Sciences

Arixtra Recall: Needle Iron Particle Discoloration in Pre-filled Syringes

BfArM issued a Drug Safety Communication regarding Viatris Healthcare Limited's Arixtra (fondaparinux sodium) pre-filled syringes. Reports indicate brown discoloration and blockage in needles caused by oxidized iron particles. Affected batches must not be dispensed or administered if discoloration is observed.

Phenhydan Injection: DHPC on Visual Particles, Filter Required

BfArM published an updated DHPC from Desitin Arzneimittel GmbH regarding Phenhydan solution for injection (phenytoin sodium), following particle contamination identified in batch 021950 during official sample analysis. The company clarified that a syringe filter with 0.2-0.45 µm pore size must be used when drawing up the solution, then removed before patient administration. This supersedes the November 2025 filter guidance which was corrected for accuracy.

Accupaque Visipaque Batch Risk Alert: Particle Contamination in Iohexol Iodixanol Solutions

GE Healthcare Buchler GmbH & Co. KG issued a Direct Healthcare Professional Communication (DHPC) alerting to a potential risk of particles in certain batches of Accupaque (iohexol) and Visipaque (iodixanol) solutions for injection filled into polypropylene bottles. The company instructs that only clear, particle-free solutions may be used per the Summary of Product Characteristics (SmPC), and this must be verified prior to administration.

Eberth Antibiotics - Outdated Package Inserts Create Patient Safety Risk

Dr. Friedrich Eberth Arzneimittel GmbH issued a Direct Healthcare Professional Communication (DHPC) via BfArM alerting that certain batches of nine antibiotic and antifungal products have outdated package inserts, creating a potential patient safety risk. Affected products include multiple strengths of cefazolin, cefotaxime, ceftazidime, ceftriaxone, levofloxacin, moxifloxacin, and voriconazole. Healthcare professionals are advised to discard outdated package inserts and refer to the current package inserts provided with the communication.

Mysimba Cardiovascular Risk and Annual Assessment Requirements

BfArM, in agreement with EMA, issued a Direct Healthcare Professional Communication regarding Mysimba (naltrexone/bupropion). The communication addresses long-term cardiovascular risks that have not been fully determined for patients treated beyond one year. New recommendations include discontinuation of treatment after one year if patients have not maintained at least 5% weight loss, and mandatory annual cardiovascular risk assessments for treatment continuation decisions.

ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF

The USPTO published patent application US20260098078A1 covering activin receptor type II chimera polypeptides for treating conditions involving muscle weakness and atrophy, bone damage, blood disorders such as anemia, thrombocytopenia, and neutropenia, as well as fibrosis, metabolic disorders, and pulmonary hypertension. The application describes extracellular ActRII chimeras optionally fused to Fc domains as therapeutic agents.

Anti-CGRP Monoclonal Antibodies for Treating Nausea and Vomiting Including CINV

The USPTO published patent application US20260098082A1 for methods using anti-Calcitonin gene related peptide (CGRP) monoclonal antibodies to treat nausea and vomiting, including chemotherapy-induced nausea and vomiting (CINV). The application, filed September 13, 2023, claims methods of preventing and counteracting CINV by targeting CGRP, a neuropeptide associated with emetic responses to chemotherapy and other triggers.

Cμ4 Region for Multi-Specific Antibody Chain Pairing

USPTO published patent application US20260098094A1 assigned to DNA Twopointo, Inc. covering multi-specific antibodies with IgM Cμ4 region pairing domains for correct heavy and light chain pairing. The invention promotes correct chain combinations and disfavors incorrect pairings in bispecific antibodies. The application was filed November 21, 2025.

CD7 Antibody Antagonists for Therapeutic Applications

USPTO published patent application US20260098089A1 titled 'CD7 Antibody Antagonists for Therapeutic Applications' filed September 8, 2025 by inventors E-Chiang Lee, Gwenoline Borhis, Cassandra Van Krinks, Lucy Hepburn, Luke Bayliss, and Miha Kosmac. The application covers Cluster of Differentiation 7 (CD7) antibody antagonists and fragments for therapeutic uses, including methods, uses, and combinations. Patent applications establish priority dates and filing status but do not yet grant enforceable intellectual property rights.

Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis US20260098088A1

USPTO published patent application US20260098088A1 assigned to Disc Medicine, Inc. The application covers anti-hemojuvelin (HJV) antibodies and methods for treating myelofibrosis and associated conditions. Inventors include Maria Beconi, John Quisel, Brian MacDonald, Steven Robinette, Bernhard Mueller, Andreas Popp, and Jennifer M. Perez. CPC classifications include C07K 16/28 and related antibody technology classes.

Modified Protein Scaffold Patent by Evolveritas

The USPTO published patent application US20260098080A1 for a modified protein scaffold comprising amino acid sequence SEQ ID NO: 115 with specific amino acid modifications in defined positions. The application was filed by Evolveritas Biotechnológiai Korlátolt Felelősségű Társaság, a Hungarian biotechnology company, with eight named inventors. The claimed protein scaffold includes segment formula Ih-mod GX1CX1VX2X3X4X5 and is intended for pharmaceutical preparations, kits, and screening procedures.

HIV/HBV Treatment Using CD8-Targeting Fusion Proteins

USPTO published patent application US20260098090A1 on April 9, 2026, disclosing fusion proteins for treating chronic viral infections including HIV and HBV. The application describes methods using CD8-targeting fusion proteins comprising antibodies specific to CD8b or CD8ab antigens combined with cytokines, chemokines, or growth factors. Inventors are Kelly Dare Moynihan, Yik Andy Yeung, and Ivana Djuretic, with filing date September 28, 2023.

Protein Crystallization Method, Multiple Protein Feeds

Protein Crystallization Method, Multiple Protein Feeds

High-Purity Recombinant Human Albumin Preparation Method

Tonghua Anrate Biopharmaceutical Co., Ltd. has filed USPTO Patent Application US20260098079A1 for a method of preparing high-purity recombinant human albumin using medium-long-chain fatty acid ligands and ion exchange chromatography. The application discloses a process where oleic acid, myristic acid, sodium palmitate, and sodium stearate are combined with recombinant human albumin in defined molar ratios with poloxamer to achieve high stability and purity through sequential anion and/or cation chromatography to remove truncated and modified albumins.

Guide Element for Intravascular Access Device - Patent Application US20260097186A1

USPTO published patent application US20260097186A1 for a guide element for intravascular access devices. The invention includes a needle inside a catheter lumen with a working space configured to receive tools, and a guide element with annular elements to control its distal end. The application was filed on September 20, 2023, under application number 19113880.

Flexible Elongate Device with Variable Bending Stiffness

USPTO published patent application US20260097185A1 titled 'Systems and Methods for Varying Bending Stiffness of a Flexible Elongate Device.' The application, filed September 18, 2023 under application number 19112852, discloses a flexible elongate medical device comprising an articulable distal section and a non-articulable proximal section with varying bending stiffness along its length. Inventors are Rumen Deyanov and Russell Field.

Guidewire with Multi-Edge Profile for Enhanced Torque and Reduced Friction

USPTO published patent application US20260097187A1 for a guidewire with a multi-edge profile designed to improve torque transmission and reduce friction during intravascular navigation. The application includes helical configurations with discrete peaks and valleys, variable pitch sections, and polymer jackets with hydrophilic coatings. The system may include diagnostic catheters deliverable simultaneously with main catheters without additional support.

Neuravi Catheter Navigation Device Minimizes Vessel Bifurcation Catching

USPTO published patent application US20260097189A1 for Neuravi Limited, filed October 9, 2024, covering an endovascular navigation device for use with funnel catheters. The device features a radially expandable section positioned between a tapered distal section and proximal section, designed to prevent the free terminating distal edge of a funnel catheter from catching at bifurcated vessels during navigation. The expandable section expands to match the catheter's maximum inner diameter when deployed. The invention addresses complications in catheter procedures at vessel bifurcations.

Electronic Emulsion Release Device with Microneedle Transdermal Delivery

The USPTO published patent application US20260097192A1 for an electronic device for releasing emulsion using microneedle transdermal delivery technology. The application was filed by KT & G Corporation and covers a device including a cartridge accommodation part, crushing circuit, processor, transfer circuit, and microneedle for discharging emulsion through the skin. The invention has CPC classifications primarily in A61M medical device technology.

Cochlear Implant Lead Insertion Site Access System and Methods

USPTO published patent application US20260097191A1 for a system and methods for accessing a cochlear implant lead insertion site under direct visualization. Inventors Hugo Peris, Benson Jung, and Kevin W. Sacherman filed the application on December 12, 2025. The system enables delivery of formulations to the middle ear and cochlear implant lead insertion sites.

Protective Assembly for Sensors in Medical Devices

USPTO published patent application US20260098776A1 for a protective assembly for sensors in medical devices. The invention comprises a substrate with an enclosing port containing electronic components wire-bonded to the substrate, covered by gel material and a fluoropolymer polyimide film (FEP). Medical device manufacturers developing sensor technologies should review this patent for potential overlap with their own IP portfolios.

Multifunction Skin Treatment Device With Detachable Heads, Auto-Detection, Serum Application

USPTO published Application US20260097193A1 for a multifunction skin treatment device with detachable treatment heads, automatic function detection, and integrated serum application. Invented by Shaul Rappaport, the device enables releasable attachment of various function heads for different treatments and a skin serum vial. The device automatically detects the attached function head type and adjusts operation accordingly, and also detects when a serum vial is fluidly connected.

Steerable Catheter Articulation State Indicator Patent

Steerable Catheter Articulation State Indicator Patent

Cells, Organs with Modified Genes for Xenograft Tolerance

Cells, Organs with Modified Genes for Xenograft Tolerance

Low Dose Psilocybin in Foodstuff and Microbes for Same

USPTO published patent application US20260098286A1 by ATX PHARMERS LLC covering engineered microbes transformed with psilocybin genes under weak or medium-level promoters to produce low levels of psilocybin, with applications in microdose and sub-microdose foodstuff production. No compliance obligations or deadlines are imposed by this publication.

Affinity Chromatography Column for Cell Binding

USPTO published patent application US20260098840A1 by TQ Therapeutics GmbH for a column design for affinity chromatography. The invention comprises a column body with a retention volume containing a stationary phase, open ends for cell addition/removal, and obstacles such as grids or pins. The application covers the column design, a system of columns, and methods for binding cells using the disclosed technology.

Cre-Lox AAV Gene Therapy Reconstitution System for Large Gene Delivery

The USPTO published patent application US20260098279A1 for a Cre-Lox AAV gene therapy system enabling delivery of therapeutic genes up to 16kb using up to four adeno-associated virus vectors with sequence-specific recombination. The invention by inventor Seongjin Seo includes novel lox site embodiments for near-unidirectional recombination. Applications include treatment of genetic disorders such as IFT140-associated retinitis pigmentosa and other retinal degeneration conditions.

Compositions and Methods for Screening Mutations in Thyroid Cancer

The USPTO published patent application US20260098297A1 on April 9, 2026, disclosing methods for screening mutations in thyroid cancer to determine whether patients with indeterminate thyroid nodules should undergo diagnostic surgery. The application covers screening patient thyroid nodules and detecting alterations in target nucleic acid sequences corresponding to thyroid cancer-related genes. Six inventors are named including Shih-Min Cheng, Joseph Catanese, and Andrew Grupe. Filing date was December 9, 2025.

Patent: Acetyl Glucosamine Improves Cognition

Patent: Acetyl Glucosamine Improves Cognition

Antibacterial Compositions with Avermectin and Melatonin for Demodex Blepharitis Treatment

USPTO published patent application US20260097059A1 covering pharmaceutical compositions for treating Demodex blepharitis. The compositions include avermectin compounds (such as ivermectin derivatives) and melatonin, with optional concentrations under 1 wt %. The application also discloses wipe devices incorporating these treatment compositions. Inventor Rolando Toyos filed the application on January 30, 2025, with publication on April 9, 2026.

SGLT-2 Inhibitor Pharmaceutical Composition for Diabetes Treatment

The USPTO published patent application US20260097058A1 for a pharmaceutical composition containing SGLT-2 inhibitors for treating diabetes mellitus, impaired glucose tolerance, hyperglycemia, and metabolic disorders. Inventors include Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas, Uli Christian Broedl, and Rolf Grempler. The application was filed on December 11, 2025.

Implantable Pressure Sensor Arrangement for Electronic Implantable Device

USPTO published patent application US20260096889A1 for an implantable pressure sensor arrangement designed for electronic implantable devices. The invention features a metal housing with flexible metal diaphragm positioned in a fluid control system manifold, configured to convert fluid pressure into electrical signals. The application was filed on October 4, 2024, under application number 18906871.

Minimally Invasive Glaucoma Surgery Device and Ocular Implant

USPTO has published patent application US20260096926A1 for a minimally invasive glaucoma surgery device and ocular implant by inventors Houfar Sekhavat and Nir Shoham-Hazon. The device is designed for office-based or operating room bleb forming procedures and includes a proximal segment for user grasping, a distal segment with a piercing member, and a pivot point mechanism allowing rotation between locked and unlocked configurations. The application was filed on October 24, 2025.

Implantable Pressure Sensor Method Described

Implantable Pressure Sensor Method Described

Eye Implant Device with Arcuate Scaffold for Drug Delivery

USPTO published patent application US20260096927A1 for an aqueous humor outflow device featuring an arcuate scaffold for drug delivery. The arcuate scaffold extends continuously circumferentially and is sized to fit within the conventional aqueous humor outflow pathway of a mammalian eye. Inventors Douglas Cali and David Richardson disclosed that the scaffold contains docking stations or ports for retaining drug eluting or drug delivery implant devices.

Systems and Methods for Anchoring an Implant (US20260096812A1)

The USPTO published patent application US20260096812A1 titled 'Systems and Methods for Anchoring an Implant' filed by inventors Khairkhahan, Lesh, Klenk, Mar, Tene, and Tun. The application covers devices and methods for anchoring medical implants including anchors, sutures, clips, and tools. Filing date was September 23, 2025, with application number 19337424. The disclosed anchors could be utilized to secure cardiac implants such as coaptation assistance devices, annuloplasty rings, artificial valves, cardiac patches, sensors, pacemakers, mitral valve rings, or artificial mitral valves.

2026 White Collar Year in Preview: Healthcare Fraud, FCA, HIPAA Enforcement

Foley Hoag LLP published its 2026 White Collar Year in Preview ebook analyzing anticipated enforcement trends across healthcare fraud, False Claims Act enforcement, HIPAA enforcement, SEC/CFTC/PCAOB priorities, anti-corruption, and international trade. The publication examines steady enforcement activity, evolving regulatory priorities, and significant court decisions expected to shape compliance and risk management strategies for organizations in 2026.

Long Anticipated Medicare Advantage Compliance Guidance Heightens Investor and Provider Scrutiny

HHS-OIG issued its Industry Compliance Program Guidance for Medicare Advantage Organizations (MA ICPG), the first such guidance in over 25 years. The voluntary, nonbinding guidance signals heightened enforcement priorities and serves as a compliance benchmark for plans, providers, and investors. In 2024, Medicare Advantage covered 54% of all Medicare enrollees with estimated government spending of $462 billion.

National Fraud Enforcement Division Shifts Healthcare Fraud Enforcement

On April 7, 2026, Acting Attorney General Todd Blanche issued a memorandum formally establishing the National Fraud Enforcement Division (NFED), consolidating DOJ's criminal fraud investigative capabilities under a single Assistant Attorney General. The NFED immediately vests operational control of the Criminal Division's Tax Section, Health Care Fraud Unit, and Market, Government, and Consumer Fraud Unit with AAG Colin McDonald. Organizations in healthcare, federal contracting, benefits administration, and trade fraud sectors face heightened federal enforcement scrutiny under the new structure.

DOJ Civil Rights Investigations Target Medical School Admissions

The Department of Justice Civil Rights Division has initiated proactive civil-rights investigations into medical school admissions practices, requesting seven years of applicant-level data and internal communications by April 24, 2026. The investigations focus on potential race discrimination following the Supreme Court's 2023 decision restricting race-conscious admissions. Schools must produce test scores, zip codes, legacy/donor ties, DEI communications, and correspondence with pharmaceutical companies. These actions represent a significant expansion of federal oversight into graduate and professional education, complementing parallel Department of Education reporting initiatives.

FinCEN Advisory Warns Financial Institutions of Healthcare Fraud Targeting Medicare and Medicaid

FinCEN issued an advisory warning financial institutions to heighten scrutiny of transactions tied to healthcare fraud targeting Medicare, Medicaid, and other federal and state healthcare benefit programs. The advisory, coordinated with the FBI and HHS-OIG, identifies fraud schemes involving shell companies, stolen identities, false beneficial ownership, phantom billing, and money laundering through digital assets and real estate. Financial institutions supporting the healthcare industry and healthcare providers are advised to take proactive measures.

FDA's 2026 General Wellness Policy and What It Means for Manufacturers of Wearable Devices

Womble Bond Dickinson analyzes FDA's General Wellness Policy finalized January 6, 2026, which describes FDA's enforcement discretion approach for low-risk products marketed for general wellness purposes. The guidance establishes two key evaluation factors: whether the product's intended use is limited to general wellness, and whether it presents low risk to users and others. The article explains how FDA evaluates wearable devices that estimate physiological measures such as blood pressure, oxygen saturation, and heart rate variability.

CMS Greenlights Hemp Product Pilot for Medicare Beneficiaries

CMS launched the Substance Access Beneficiary Engagement Incentive pilot program on April 1, 2026, allowing healthcare providers participating in CMMI models to offer hemp products to Medicare beneficiaries. Products must be federally legal hemp-derived with no more than 0.3% delta-9 THC, limited to $500 per beneficiary annually. Providers must submit CMS-approved implementation plans and quarterly reports.

FDA Issues RFI on Digital Health Clinical Trials

FDA Issues RFI on Digital Health Clinical Trials

EU Pharma Package Reforms Drug Development, Animal Testing

A&O Shearman analyzes the EU Pharma Package reforms following the Council of the European Union and European Parliament's December 2025 trilogue agreement. The provisional texts include a new Regulation and Directive covering expanded scientific advice, a shift away from animal testing, new frameworks for platform technologies, faster marketing authorization pathways, and regulatory sandboxes. These reforms aim to reduce regulatory burden and accelerate authorization procedures for medicinal products addressing unmet medical needs.

Sixteen Landmarks Illuminated Blue and Green for National Donate Life Day

NY DOH announced that 16 landmarks across New York State will be illuminated in blue and green on April 10, 2026, in honor of National Donate Life Blue & Green Day. The initiative aims to raise awareness about organ, eye, and tissue donor registration. In 2024, more than 50 percent of eligible New Yorkers joined the Donate Life Registry, now at 52.9 percent. The NY Living Donor Support Program, launched October 2025, has received 124 applications with a 100 percent acceptance rate and nearly $215,000 reimbursed to living donor applicants.

State Landmarks Illuminated Blue for World Parkinson's Day

The New York State Department of Health announced that 16 state landmarks will be illuminated blue on the evening of April 11 in recognition of World Parkinson's Day. The landmarks include One World Trade Center, Niagara Falls, Grand Central Terminal, and other notable sites. Commissioner Dr. James McDonald encouraged individuals experiencing movement difficulties to consult healthcare providers for treatment options.

EPA Honors Rhode Island Water Infrastructure Project

The EPA honored a Rhode Island water infrastructure project for its achievements. The Rhode Island Department of Health announced this recognition, highlighting the state's progress in water infrastructure improvements. No new compliance obligations or deadlines were established by this announcement.

Recombinant AAV Vectors for Treating Muscular Dystrophy

USPTO published patent application US20260097132A1 assigned to Sarepta Therapeutics, Inc. covering recombinant adeno-associated virus (rAAV) vectors for expressing human micro-dystrophin gene to treat muscular dystrophy, including Duchenne Muscular Dystrophy. The application includes methods for genotyping DMD gene to determine rAAV gene therapy contraindications. Filing date was September 22, 2023.

Fungal Spore Production Method Using Dual Liquid Medium

The USPTO published patent application US20260098242A1 covering a method for producing fungal spores using a dual liquid medium system. The first medium has a lower carbon content than the second medium. Inventors: Van De Zilver Eric, Laurens Van Leeuwen. Application filed September 26, 2023; published April 9, 2026.